Go back to the enewsletter Tauck Australia has ann

first_imgGo back to the enewsletterTauck Australia has announced three cruises commencing in April 2020 aboard Tauck’s new 84-passenger Douro Riverboat.Purpose-built by Scylla for cruising to historic quintas and picturesque villages along Portugal’s golden Douro River from coastal Porto to the Spanish border, the riverboat will feature five cabin categories: 12 Category 5 Tauck Suites, 20 Categories 4 and 3, six Category 2 cabins and four Category 1 cabins. Most have floor-to-ceiling windows with real French balconies, and all have in-room movies, mini bar, adjustable heating and cooling, private bathroom and shower with pampering toiletries. In addition to the main dining room, The Compass Rose, the ship also features Arthur’s, a second dining venue offering casual fare.An artist rendering of Tauck’s yet-to-be named Douro RiverboatCruise itineraries and dates on the 80-metre ship are as follows, with full pricing to be available in February 2019:12-day Exploring the Douro, plus Lisbon & MadridDiscover the Iberian Peninsula’s riverside gems, accompanied by two-night land stays in Lisbon and Madrid. Lisbon invites discoveries of then and now in a delightfully paced parade of monumental sites, palaces and azulejos chronicling life from Moorish times to present day. Discover fascinating Porto while in the Douro Valley, white-painted quinta estates lined with terraced vineyards, a rich multicultural heritage, unique grape varieties and a fantastic climate. Visit museums, monasteries, castles, riverside wine estates and picture-perfect villages such as Pinhão. See Madrid’s 13th-century university, Plaza Mayor, and museums royally inspired. Enjoy culinary creations that make small bites an art and a bevy of Baroque and belle époque architecture.Departures eastbound ex-Lisbon to Madrid: 8 April, 6 and 27 May, 14 July, 11 August, 8 September, 6 October 2020. Departures westbound ex-Madrid to Lisbon: 15 April, 13 May, 3 June, 21 July, 18 August, 15 September, 13 October 2020.Seven-night Douro DiscoveryStart with a two-night stay in Lisbon, setting foot where the world’s first explorers set sail and visiting a palace, historic monuments and museums. Then embark your riverboat in Porto, home to port wine, storytelling mosaics, Harry Potter influences and sightseeing aboard a 19th-century tram and a funicular railway. In the Douro River Valley, cruise through the oldest winemaking region in the world, where prehistoric artists created rock art, Romans planted vines in the second century, and monasteries, castles and quintas date back to the Middle Ages. Make this a family adventure for every age and generation exploring Portuguese ports of call from Lisbon and Porto to Pinhão and Peso da Régua, visiting landmarks on a guided tour, riding the rails back in time, hiking or bicycling through picturesque vineyard and enjoying onboard fun with parties, games and a pool on the sun deck.Departures ex-Porto (return): 24 June, 29 June, 4 July, 9 July 2020.Eight-day Villages and VintagesExperience an authentic taste of daily life in the Douro River Valley, steeped in a legacy of winemaking for more than 2,000 years. Enjoy wine tastings at picturesque quintas hosted by expert winemakers. Visit villages, a museum, a palace and a prehistoric site and view azulejo-tiled stories. In Porto, discover the essence of world-famous Port wine in the historic seaside city where it was perfected, with private tastings and sightseeing. See traditional Rabelo boats carrying barrels of regionally produced Port wine bound for aging casks in Porto, set sail from the scenic wine-terraced town of Peso da Régua as Pinhão seems to have emerged straight out of a postcard, offering up-close exploration on a choice of activities including hiking and al fresco wine tasting. Pocinho is the perfect place to visit hidden gems, like the Palaeolithic rock art of Foz Côa and medieval ramparts of Castelo Rodrigo.Departures ex-Porto (return): 3 and 24 April, 1 May and 22 May, 12 and 19 June, 30 July, 6 and 27 August, 3 and 24 September and 1, 22 and 29 October, 2020.Go back to the enewsletterlast_img read more

Watch This Worlds Biggest Tesla Summon Race Video

first_img Author Liberty Access TechnologiesPosted on April 14, 2019Categories Electric Vehicle News Tesla drivers watch as their vehicles move in and out of parking spaces with the company’s Summon mode.What’s more exciting than seeing one Tesla engaged in Summon Mode? If your answer is a dozen of them, then the Tesla Owners Club of Greater Houston has you covered.More Tesla Summon News Does Tesla Model 3 Summon Work On Snow & Ice? Watch Tesla Model 3 In Enhanced Summon Mode Pass Oncoming Vehicle: Video In what the group called the “world’s largest Tesla Summon race,” YouTube user Efrain Ayllon posted a video earlier this month of about 12 Teslas parked in a large lot while drivers stood in front of them and enabled Summon Mode to move them in and out of the perpendicular spaces.While parking assistants are quickly spreading to new cars, Tesla has been a significant promoter of them as they fit in with its Autopilot driver assistance package the company is also widely touting. CEO Elon Musk spurred more interest last week as he promised widespread Enhanced Autopilot updates being pushed to vehicles in the U.S. That change would allow users to pinpoint specific locations to summon the Tesla to, without anyone being behind the wheel, as well as the ability for the system to understand parking restriction signage.And with Tesla continuing to develop Summon Mode to the excitement of its growing fanbase, what’s to say this Texas Tesla Summon Race won’t have its record broken tomorrow? At least there’s something else all of the empty mall parking lots in the U.S. can be used for. Source: Electric Vehicle News Tesla Enhanced Summon Demo Draws Big Crowd: Videolast_img read more

For some multiple sclerosis patients knocking out the immune system might work

first_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Nearly 30 years ago, when hematologist Richard Burt saw how HSCT worked in patients with leukemia and lymphoma, he was struck by a curious effect: After those patients rebuilt their immune systems, their childhood vaccines no longer protected them, recalls Burt, now at Northwestern University’s Feinberg School of Medicine in Evanston, Illinois. Without a new vaccination, the new immune cells wouldn’t recognize viruses such as measles and mumps and launch a prompt counterattack. That suggested that in the case of an autoimmune disease, reseeding the immune system might help the body “forget” that its own cells were the enemy.Burt and others have since used HSCT for a variety of autoimmune diseases, including rheumatoid arthritis and lupus. In the past few years, several teams have reported encouraging results in MS. But only one study—which evaluated just 17 patients—directly compared HSCT to other available drug treatments.In the new trial, Burt and his colleagues recruited 110 people with the most common form of MS, known as relapsing-remitting. In that form of the disease, patients can go long periods without symptoms—which include muscle weakness and vision problems—before inflammation flares up. Trial participants had at least two such relapses in the previous year, despite being on one of several approved MS drugs.Half the participants continued with drug treatment but switched from a drug that wasn’t working for them to a drug of a different class. The other half underwent HSCT. First, the researchers collected their blood to reinfuse later. Then, they gave patients a combination of drugs to kill most of their immune cells. In this trial, the patients would have regenerated their own immune systems with stem cells in bone marrow that were spared annihilation, Burt notes. But they received the reinfusion of their own stem cell-rich blood to help speed recovery by several days.A year later, the researchers evaluated how far the disease had progressed in each of the patients. According to a  zero-to-10 scale of disability that includes measures of strength, coordination, and speech, roughly 25% of those in the drug treatment group showed at least a one-point worsening in their score, compared with just 2% of those in the transplant group, the researchers report online today in The Journal of the American Medical Association (JAMA).MRI scans also revealed less extensive brain lesions in the transplant group and improvements in a patient survey about quality of life. (Survey scores worsened slightly in the drug-treated group.) Five years after treatment, about 15% of people in the transplant group had had a relapse, versus about 85% of the control group.The two groups diverged “in a massive way,” Muraro says. But he adds that two of the most effective MS drugs weren’t included in the control group. One, ocrelizumab, had not been approved when the study was enrolling participants. Another, alemtuzumab, was excluded because it also depletes immune cells and might have increased the risk of complications in patients from the control group who were later allowed “cross over” and undergo HSCT. That “doesn’t detract from the beauty of the results,” Muraro says, but it means future studies should compare HSCT strictly with the most potent drugs on the market.In the new study, where patients spent about 2 weeks in the hospital, there were no deaths or life-threatening complications. But there is still “a hard core of skepticism” about HSCT among physicians, Muraro says, largely because chemotherapy carries risks of infections and complications. As University of Ottawa hematologist Harold Atkins points out in a cautious editorial in JAMA today, researchers have reported deaths in trials for other autoimmune diseases using the same HSCT procedure. But Muraro notes that the overall mortality rate associated with HSCT for MS now stands at less than 1%.Burt acknowledges the procedure has risks—and that most MS patients likely aren’t candidates. HSCT should be considered for people with the relapsing-remitting disease and frequent relapses, he says, before they enter a progressive phase of the disease, in which symptoms gradually worsen without intervening attacks. He estimates that about 15% to 20% of people with MS are candidates for HSCT.Meanwhile, there’s evidence of growing enthusiasm for the procedure, at least in Europe. A recent survey found a sharp spike over the past 5 years in the use of patients’ own stem cells to treat autoimmune diseases. The source of that spike, the study said, was an increase in clinical centers using the approach to treat MS. In multiple sclerosis (MS), a disease that strips away the sheaths that insulate nerve cells, the body’s immune cells come to see the nervous system as an enemy. Some drugs try to slow the disease by keeping immune cells in check, or by keeping them away from the brain. But for decades, some researchers have been exploring an alternative: wiping out those immune cells and starting over.The approach, called hematopoietic stem cell transplantation (HSCT), has long been part of certain cancer treatments. A round of chemotherapy knocks out the immune system and an infusion of stem cells—either from a patient’s own blood or, in some cases, that of a donor—rebuilds it. The procedure is already in use for MS and other autoimmune diseases at several clinical centers around the world, but it has serious risks and is far from routine. Now, new results from a randomized clinical trial suggest it can be more effective than some currently approved MS drugs.“A side-by-side comparison of this magnitude had never been done,” says Paolo Muraro, a neurologist at Imperial College London who has also studied HSCT for MS. “It illustrates really the power of this treatment—the level of efficacy—in a way that’s very eloquent.” Click to view the privacy policy. Required fields are indicated by an asterisk (*) For some multiple sclerosis patients, knocking out the immune system might work better than drugs Blood stem cells (depicted here, yellow, in bone marrow) regenerated the immune system after chemotherapy in a new trial for multiple sclerosis.center_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Dennis Kunkel Microscopy/Science Source Email By Kelly ServickJan. 15, 2019 , 11:15 AMlast_img read more